Business Context and Reporting Period
This Form 8-K filing by Processa Pharmaceuticals, Inc. (PCSA) covers the event date of January 6, 2026. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on regulatory compliance status rather than financial performance.
Material Changes
On January 6, 2026, the Company received written notification from the NASDAQ Stock Market Listing Qualifications Staff confirming it has regained compliance with the $1.00 minimum closing bid price requirement (NASDAQ Listing Rule 5550(a)(2)). Consequently, the matter regarding the Company's listing status is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks and contingencies. The document serves exclusively to announce the resolution of the minimum bid price deficiency.
Investor Verification Checklist
- Verify the current trading price of PCSA to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the Company's continued good standing on the Nasdaq Capital Market via the exchange's official website.
- Review subsequent filings for any new compliance notices or financial updates.